Greenwich Lifesciences Inc (GLSI)

Greenwich Lifesciences Inc (GLSI) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $226M; returns 1 day +3.6%, 1 week +10.2%, 1 year +74.4%.

Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company with a singular focus on developing its lead and only product candidate, GLSI-100 (also known as GP2). GLSI-100 is a peptide-based immunotherapy designed to prevent the recurrence of breast cancer in patients with HER2/neu-expressing tumors.

Groups GLSI belongs to

• Healthcare
• Biotechnology
• Clinical Stage Biotech
• Oncology
• Breast Cancer Treatment
• Biopharmaceutical
• Immunotherapy
• Clinical Stage
• Cancer Therapeutics
• Life Sciences

GLSI financial model: income statement, cash flow and balance sheet